This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NFC1, NFC-1, MDGN-001, MDGN001
Description: NFC-1 is a small molecule, non-stimulant antagonist of multiple metabotropic glutamate receptors (mGluR; 1/3/5/7/8). NFC-1 also up-regulates GABAB receptors.
NFC-1 was originally developed by neuroFix Therapeutics.
Medgenics and neuroFix
In September 2015, Medgenics announced its acquisition of neuroFix Therapeutics. Medgenics acquired all outstanding shares of neuroFix for upfront consideration of $2 million cash, a series of performance-based milestone payments and sales royalties.
Additional information available to subscribers only: